Download PDF

1. Company Snapshot

1.a. Company Description

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally.It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma.The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.


It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers much earlier in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment.In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intramuscular injection of adrenaline for the treatment of acute life-threatening allergic reactions including Anaphylaxis.ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.

Show Full description

1.b. Last Insights on ALK

ALK-Abelló A/S's recent performance was driven by strong Q2 results, exceeding expectations with 12% organic revenue growth and a 41% increase in operating profit. The company's upgraded full-year revenue outlook, now expecting 12-14% growth, reflects higher-than-expected revenue in Europe and an improved outlook for the rest of the year. Sales of adrenaline autoinjectors and tablets contributed to the strong performance, with the company's tree pollen tablet, ITULAZAX, receiving a positive recommendation from NICE for use in the UK health system.

1.c. Company Highlights

2. ALK's Q4 and Full Year 2025 Results: Strong Revenue Growth and Strategic Progress

ALK reported a robust financial performance for Q4 and Full Year 2025, with revenue increasing by 17% and 15% respectively. The company's EBIT margin expanded to 22% in Q4 and 26% for the full year, driven by strategic investments and diligent cost control. Earnings per share (EPS) for the full year came in at 1.2, slightly below estimates of 1.3. Revenue for 2025 reached DKK 6.3 billion, exceeding initial expectations. The gross margin stood at 67%, and EBIT increased to DKK 1.65 billion.

Publication Date: Feb -24

📋 Highlights
  • Q4 Revenue Growth:: Increased by 17%, driven by strong performance in geographies, tablets in Europe, and anaphylaxis.
  • Full-Year Revenue 2025:: Rose to DKK 6.3 billion, a 15% growth, exceeding initial expectations with a gross margin of 67%.
  • EBIT Margin Expansion:: Full-year EBIT margin improved to 26%, up 53% year-over-year, reflecting higher sales and cost control.
  • Germany Market Share:: EURneffy captured 18% value share in Germany by year-end 2025 with 11-12% volume share via digital efforts.
  • Dividend Recommendation:: Board proposed DKK 355 million dividend for 2025, signaling confidence in financial performance and growth prospects.

Segment Performance

The company's tablet sales grew by 17% in 2025, driven by the expansion of the patient base in Europe and Canada. SCIT and SLIT drops delivered a 5% sales growth, while anaphylaxis and other product sales increased by 34%. In Europe, revenue grew 14% with tablets driving 19% growth. North America saw revenue increase 19% driven by tablets and anaphylaxis, while international markets recorded revenue growth of 16%.

Guidance and Outlook

ALK expects double-digit revenue growth in 2026, with an EBIT margin of around 25%. The company anticipates organic growth across all sales regions and product groups, driven by volume growth. Tablet sales are expected to grow by double digits, fueled by the continued expansion of prescriber and patient bases. Anaphylaxis and other product sales are also projected to grow by double digits, led by the commercialization of neffy.

Valuation and Metrics

With a P/E Ratio of 39.13 and an EV/EBITDA of 23.33, the market appears to be pricing in significant growth expectations. The company's ROE stands at 19.83%, indicating a strong return on equity. The dividend yield is currently 0.0%, but the Board of Directors recommends a dividend payment of DKK 355 million for 2025. The Free Cash Flow Yield is 3.17%, suggesting a reasonable cash generation capability.

Pipeline Progress

ALK is making progress in its pipeline, including the initiation of a Phase II clinical trial for its peanut SLIT tablet, which has received Fast Track Designation from the FDA. The company is also exploring new areas, such as urticaria, through partnerships and business development. The top-line results for the peanut allergy study are expected in Q2 2026.

3. NewsRoom

Card image cap

ALK and GenSci partner to expand the AIT market in China

Sep -17

Source:

Card image cap

Is Now the Moment to Reassess ALK-Abelló After Shares Jump 24% in 2025?

Sep -09

Source:

Card image cap

Could Direct Executive Oversight in Core Regions Reshape ALK-Abelló's Strategic Path (CPSE:ALK B)?

Sep -08

Source:

Card image cap

Real-world evidence supports clinical effectiveness of the neffy® nasal adrenaline spray

Sep -08

Source:

Card image cap

ALK expands the Executive Leadership Team to include key commercial regions

Sep -04

Source:

Card image cap

Six-month interim report (Q2) 2025 (unaudited)

Aug -21

Source:

Card image cap

Invitation to the presentation of ALK’s first six months (Q2) 2025 results on Thursday, 21 August 2025

Aug -14

Source:

Card image cap

ALK upgrades its full-year revenue outlook

Aug -12

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.68%)

6. Segments

Sublingual Immunotherapy-Tablets

Expected Growth: 10%

ALK-Abelló A/S's Sublingual Immunotherapy-Tablets growth is driven by increasing adoption in allergy treatment, rising prevalence of allergies, and growing demand for convenient, self-administered therapies. Expanding product offerings, strategic partnerships, and geographic expansion into new markets also contribute to the 10% growth.

Subcutaneous Immunotherapy/Sublingual Immunotherapy-Drops

Expected Growth: 12%

ALK-Abelló A/S's Subcutaneous Immunotherapy/Sublingual Immunotherapy-Drops growth is driven by increasing adoption in allergy treatment, rising prevalence of allergies, and growing demand for convenient and patient-friendly therapies. Additionally, expanding product offerings, strategic partnerships, and geographic expansion into emerging markets contribute to the 12% growth.

Other

Expected Growth: 9%

ALK-Abelló A/S's 9% growth is driven by increasing demand for allergy immunotherapy treatments, expansion into new markets, and strategic partnerships. The company's strong R&D pipeline, focus on digitalization, and cost-saving initiatives also contribute to its growth. Additionally, the rising prevalence of allergies and growing awareness of treatment options support the company's upward trend.

7. Detailed Products

ACARIZAX

Acarizax is a sublingual allergy immunotherapy tablet for the treatment of house dust mite-induced allergic rhinitis.

GRAZAX

Grazax is a sublingual allergy immunotherapy tablet for the treatment of grass pollen-induced allergic rhinitis.

MITICURE

Miticure is a sublingual allergy immunotherapy tablet for the treatment of mite-induced allergic rhinitis.

RAGWITEK

Ragwitek is a sublingual allergy immunotherapy tablet for the treatment of ragweed pollen-induced allergic rhinitis.

ODACTRA

Odactra is a sublingual allergy immunotherapy tablet for the treatment of house dust mite-induced allergic rhinitis.

8. ALK-Abelló A/S's Porter Forces

Forces Ranking

Threat Of Substitutes

ALK-Abelló A/S operates in a niche market with limited substitutes, but there are some alternatives available, which reduces the threat of substitutes.

Bargaining Power Of Customers

ALK-Abelló A/S has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.

Bargaining Power Of Suppliers

ALK-Abelló A/S relies on a few key suppliers for raw materials, which gives them some bargaining power. However, the company's size and reputation help to mitigate this risk.

Threat Of New Entrants

The pharmaceutical industry has high barriers to entry, including significant regulatory hurdles and high research and development costs, which reduces the threat of new entrants.

Intensity Of Rivalry

The pharmaceutical industry is highly competitive, with many established players competing for market share. ALK-Abelló A/S operates in a niche market, but still faces intense competition from other companies.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 14.68%
Debt Cost 3.95%
Equity Weight 85.32%
Equity Cost 6.04%
WACC 5.73%
Leverage 17.20%

11. Quality Control: ALK-Abelló A/S passed 8 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Genmab

A-Score: 5.8/10

Value: 3.2

Growth: 9.7

Quality: 9.5

Yield: 0.0

Momentum: 8.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
ALK-Abelló

A-Score: 5.0/10

Value: 0.2

Growth: 8.2

Quality: 7.8

Yield: 0.0

Momentum: 9.0

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Alkermes

A-Score: 5.0/10

Value: 4.9

Growth: 8.4

Quality: 8.9

Yield: 0.0

Momentum: 4.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Jazz Pharmaceuticals

A-Score: 4.9/10

Value: 4.8

Growth: 7.1

Quality: 4.7

Yield: 0.0

Momentum: 9.5

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Camurus

A-Score: 4.7/10

Value: 0.2

Growth: 9.3

Quality: 9.1

Yield: 0.0

Momentum: 7.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Zealand Pharma

A-Score: 3.3/10

Value: 7.0

Growth: 2.2

Quality: 9.9

Yield: 0.0

Momentum: 0.5

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

216.2$

Current Price

216.2$

Potential

-0.00%

Expected Cash-Flows